Table 1.

Distribution of influenza article types and outcome indicators.

Study Design	Source	Groups	N	Outcomes
				Main Outcomes						Secondary Outcomes
				Fever	Headache	Myalgia	Cough	Sorethroat	Malaise	Hospitalization	Side effects
Meta	Li J. H. et al., 2016	1.Ma Huang Tang plus NAIs vs. NAIs 2. Ma Huang Tang vs. NAIs	30 studies, 3,444 cases	↑	↑	↑			↑	↑	↑
	Yoshino et al., 2019 Hu et al., 2017	1.TCM VS oseltamivir 2.TCM + oseltamivir vs. oseltamivir Andrographis paniculata vs. placebo	12 studies, 1,170 cases 33 studies, 7,175 cases	↑			↑	↑		↑
Randomized Controlled Trial	Wang et al., 2011	maxingshigan–yinqiaosan vs. Oseltamivir	410 cases	↑	↑		↑	↑
	Wang et al., 2010	Antiwei vs. placebo	480 cases	↑	↑	↑	↑	↑
	Li et al., 2013	Echinacea vs. Placebo	136 cases
	Nabeshima et al., 2012	Jinhua Qinggan Granules vs. Placebo	28 cases	↑	↑	↑	↑	↑			↑
	Lindenmuth et al., 2013	Maoto VS oseltamivir vs. zanamivir	95 cases	↑	↑	↑	↑	↑			↑

The upward arrow represents the relief of symptoms after treatment.